MX349162B - Sistemas de deposito que comprende glatiramer o una sal farmacologicamente aceptable del mismo. - Google Patents

Sistemas de deposito que comprende glatiramer o una sal farmacologicamente aceptable del mismo.

Info

Publication number
MX349162B
MX349162B MX2012007760A MX2012007760A MX349162B MX 349162 B MX349162 B MX 349162B MX 2012007760 A MX2012007760 A MX 2012007760A MX 2012007760 A MX2012007760 A MX 2012007760A MX 349162 B MX349162 B MX 349162B
Authority
MX
Mexico
Prior art keywords
glatiramer
acceptable salt
pharmacologically acceptable
depot systems
effective amount
Prior art date
Application number
MX2012007760A
Other languages
English (en)
Other versions
MX2012007760A (es
Inventor
Ehud Marom
Shai Rubnov
Original Assignee
Mapi Pharma Ltd *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mapi Pharma Ltd * filed Critical Mapi Pharma Ltd *
Publication of MX2012007760A publication Critical patent/MX2012007760A/es
Publication of MX349162B publication Critical patent/MX349162B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Epoxy Resins (AREA)
  • Epoxy Compounds (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica parental de acción prolongada, caracterizada porque comprende una cantidad terapéuticamente efectiva de una sal de glatiramer farmacéuticamente aceptable, la composición está en una forma de depósito de liberación sostenida la cual libera una cantidad terapéuticamente efectiva de la sal de glatiramer farmacéuticamente aceptable durante un periodo de aproximadamente 1 sema a aproximadamente 6 meses. La composición farmacéutica además comprende al menos una droga adicional.
MX2012007760A 2010-01-04 2010-08-19 Sistemas de deposito que comprende glatiramer o una sal farmacologicamente aceptable del mismo. MX349162B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29192810P 2010-01-04 2010-01-04
PCT/IL2010/000679 WO2011080733A1 (en) 2010-01-04 2010-08-19 Depot systems comprising glatiramer or a pharmacologically acceptable salt thereof

Publications (2)

Publication Number Publication Date
MX2012007760A MX2012007760A (es) 2012-08-01
MX349162B true MX349162B (es) 2017-07-14

Family

ID=44226217

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020003805A MX2020003805A (es) 2010-01-04 2010-08-19 Sistemas de deposito que comprende glatiramer o una sal farmacologicamente aceptable del mismo.
MX2012007760A MX349162B (es) 2010-01-04 2010-08-19 Sistemas de deposito que comprende glatiramer o una sal farmacologicamente aceptable del mismo.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020003805A MX2020003805A (es) 2010-01-04 2010-08-19 Sistemas de deposito que comprende glatiramer o una sal farmacologicamente aceptable del mismo.

Country Status (20)

Country Link
US (1) US8796226B2 (es)
EP (2) EP3536333B1 (es)
JP (2) JP5916622B2 (es)
CN (3) CN107661490B (es)
AU (1) AU2010337822B2 (es)
BR (1) BR112012016459B1 (es)
CA (1) CA2784394C (es)
CY (1) CY1120975T1 (es)
DK (2) DK3536333T3 (es)
ES (2) ES2928900T3 (es)
HK (2) HK1245667A1 (es)
HR (2) HRP20221208T1 (es)
HU (2) HUE060304T2 (es)
LT (2) LT3536333T (es)
MX (2) MX2020003805A (es)
PL (2) PL3536333T3 (es)
PT (2) PT2398488T (es)
SI (1) SI2398488T1 (es)
TR (1) TR201818858T4 (es)
WO (1) WO2011080733A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8377885B2 (en) 2010-01-04 2013-02-19 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
ES2601892T3 (es) 2011-04-21 2017-02-16 Mapi Pharma Limited Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes
CA2848331C (en) 2011-09-18 2020-07-21 Bio Plasmar Ltd Bio-degradable compositions and use thereof
WO2014128079A1 (en) * 2013-02-19 2014-08-28 Synthon B.V. Glatiramer acetate multidose formulation
CN103169670B (zh) * 2013-03-22 2016-07-06 深圳翰宇药业股份有限公司 一种醋酸格拉替雷微球及其制备方法
CA2920758A1 (en) * 2013-07-29 2015-02-05 Aizant Drug Research Solutions Pvt Ltd Pharmaceutical compositions of fingolimod
US20160338967A1 (en) * 2013-12-23 2016-11-24 Kineta One, Llc Sustained release depot formulations of therapeutic proteins, and uses thereof
US10493122B2 (en) 2014-03-17 2019-12-03 Mapi Pharma Ltd. Sublingual delivery of glatiramer acetate
KR20180054627A (ko) 2015-09-21 2018-05-24 테바 파마슈티컬스 인터내셔널 게엠베하 서방형 올란자핀 제제
US20210220428A1 (en) * 2016-06-30 2021-07-22 Stem Cell Medicine Ltd. Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
EP3503907B1 (en) * 2016-08-28 2024-03-13 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
JP7193448B2 (ja) * 2016-08-31 2022-12-20 マピ ファーマ リミテッド 酢酸グラチラマーを含むデポシステム
EP3515404B1 (en) * 2016-10-28 2020-03-18 Spinethera Pharmaceutical compositions and uses thereof
JP2020511483A (ja) 2017-03-20 2020-04-16 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ 徐放性オランザピン製剤
EP3600553A4 (en) * 2017-03-26 2020-09-02 Mapi Pharma Ltd. GLATIRAMER DEPOT SYSTEMS FOR TREATMENT OF PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS
EP3624815A4 (en) * 2017-05-15 2021-01-20 Stem Cell Medicine Ltd. TREATMENT OF MULTIPLE SCLEROSIS WITH LONG-ACTING GLATIRAMER AND ADAPTIVE STEM CELLS
IL269893B2 (en) 2017-05-15 2023-10-01 Stem Cell Medicine Ltd Treatment of multiple sclerosis using stem cells derived from adipose tissue
EP3645029B1 (en) 2017-06-26 2023-01-18 Institut Pasteur Treatments to eliminate hiv reservoirs and reduce viral load
EP4171613A4 (en) * 2020-06-29 2024-06-05 Mapi Pharma Ltd LOW RAPID RELEASE LIRAGLUTIDE DEPOSITORY SYSTEMS
WO2022094473A1 (en) * 2020-11-02 2022-05-05 Simcha IL-18, Inc. Interleukin-18 variants and methods of use
US20240100012A1 (en) 2021-01-18 2024-03-28 Mark Hasleton Pharmaceutical dosage form
WO2022163966A1 (ko) * 2021-01-29 2022-08-04 주식회사 티온랩테라퓨틱스 초기 방출 제어된 데포 조성물 및 이의 제조방법
US11865213B2 (en) 2021-07-05 2024-01-09 Mapi Pharma Ltd. Semaglutide depot systems and use thereof
CA3227324A1 (en) 2021-07-06 2023-01-12 Mark Hasleton Treatment of serotonin reuptake inhibitor withdrawal syndrome
WO2023170493A1 (en) * 2022-03-07 2023-09-14 Hadidi Naghmeh Drug delivery using a parenteral pharmaceutical composition
WO2024054879A1 (en) * 2022-09-06 2024-03-14 Regents Of The University Of Michigan Biodegradable polymeric particles for delivery of positively charged therapeutic agents

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IL36670A (en) 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5800808A (en) 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5858964A (en) 1995-04-14 1999-01-12 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
IT1276690B1 (it) 1995-06-09 1997-11-03 Ira Srl Sistema di inclusione a rilascio controllato di acido glicolico in beta-ciclodestrine e procedimento di preparazione di detto sistema
US6214791B1 (en) 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
TW577759B (en) * 1997-04-18 2004-03-01 Ipsen Pharma Biotech Sustained release compositions in the form of microcapsules or implants and the process for their preparation
ES2527760T3 (es) 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
WO2000005250A1 (en) 1998-07-23 2000-02-03 Yeda Research And Development Co., Ltd Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides
WO2000027417A1 (en) 1998-11-12 2000-05-18 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating gvhd and hvgd
AU780188B2 (en) 2000-01-20 2005-03-03 Yeda Research And Development Co. Ltd. The use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy
WO2001093893A2 (en) * 2000-06-07 2001-12-13 Yeda Research And Development Co. Ltd. The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy
US6835711B2 (en) 2001-06-28 2004-12-28 Yeda Research And Development Co. Ltd. Use of poly-Glu,Tyr for neuroprotective therapy
KR100892333B1 (ko) * 2001-07-10 2009-04-08 테바 파마슈티컬 인더스트리즈 리미티드 0차, 0차-2상, 증가적 또는 감소적 약물 전달을 위한 약물전달 시스템
JP5010798B2 (ja) * 2001-10-03 2012-08-29 プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ 自己免疫疾患を抑制するためのコポリマー、及びその使用方法
US8871241B2 (en) 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
CN1398584A (zh) * 2002-07-15 2003-02-26 裴福兴 一种bFGF－PLGA缓释微球及其制备方法和用途
US20050142205A1 (en) * 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
JP2007531701A (ja) * 2003-07-18 2007-11-08 バクスター・インターナショナル・インコーポレイテッド 制御された相分離により調製される小球状粒子の作製方法、使用および組成物
US20060276390A1 (en) * 2003-07-31 2006-12-07 Yeda Research And Development Co. Ltd. Combined treatments comprising synthetic peptide copolymers for preventing graft rejection
JP2007509981A (ja) * 2003-10-31 2007-04-19 テバ ファーマシューティカル インダストリーズ リミティド 薬物デリバリー用ナノ粒子
EP2633853A1 (en) * 2004-01-12 2013-09-04 The Trustees of The University of Pennsylvania Long-term delivery formulations and methods of use thereof
BRPI0508382A (pt) 2004-03-01 2007-07-31 Peptimmune Inc métodos e composições para tratamento de doenças auto-imunes
US7655221B2 (en) 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
US7517856B2 (en) * 2005-10-11 2009-04-14 Ben-Gurion University Of The Negev Research And Development Authority Bioconjugates comprising sulfated polysaccharides and their uses
WO2008075365A1 (en) 2006-12-20 2008-06-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions and methods for treatment of age related degeneration of the retina
ES2402175T3 (es) * 2007-07-11 2013-04-29 Medicinova, Inc. Tratamiento de una enfermedad neurodegenerativa progresiva con ibudilast
EP2318012A4 (en) 2008-07-25 2011-08-24 Univ Johns Hopkins METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING AUTOIMMUNE DISEASES
US8377885B2 (en) 2010-01-04 2013-02-19 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof

Also Published As

Publication number Publication date
EP3536333B1 (en) 2022-08-03
CA2784394A1 (en) 2011-07-07
LT3536333T (lt) 2022-11-10
EP2398488A1 (en) 2011-12-28
HRP20221208T1 (hr) 2022-12-09
HUE040390T2 (hu) 2019-03-28
MX2012007760A (es) 2012-08-01
PL3536333T3 (pl) 2022-12-05
LT2398488T (lt) 2019-01-25
CN107661490A (zh) 2018-02-06
WO2011080733A1 (en) 2011-07-07
JP5916622B2 (ja) 2016-05-11
DK2398488T3 (en) 2019-01-28
US8796226B2 (en) 2014-08-05
JP2016074696A (ja) 2016-05-12
PL2398488T3 (pl) 2019-03-29
BR112012016459A2 (pt) 2017-10-03
PT3536333T (pt) 2022-11-11
EP2398488A4 (en) 2014-06-11
CY1120975T1 (el) 2019-12-11
US20120015891A1 (en) 2012-01-19
CN107184954A (zh) 2017-09-22
AU2010337822B2 (en) 2016-03-17
JP2013516403A (ja) 2013-05-13
DK3536333T3 (da) 2022-10-24
PT2398488T (pt) 2018-12-20
EP3536333A1 (en) 2019-09-11
CN107661490B (zh) 2021-12-31
SI2398488T1 (sl) 2019-02-28
ES2699692T3 (es) 2019-02-12
CA2784394C (en) 2016-12-13
HUE060304T2 (hu) 2023-02-28
ES2928900T3 (es) 2022-11-23
BR112012016459B1 (pt) 2020-01-14
MX2020003805A (es) 2022-05-05
HRP20182076T1 (hr) 2019-02-08
CN102686235A (zh) 2012-09-19
HK1244430A1 (zh) 2018-08-10
TR201818858T4 (tr) 2019-01-21
AU2010337822A1 (en) 2012-07-12
HK1245667A1 (zh) 2018-08-31
EP2398488B1 (en) 2018-11-14

Similar Documents

Publication Publication Date Title
MX2012007760A (es) Sistemas de deposito que comprende glatiramer o una sal farmacologicamente aceptable del mismo.
UA108885C2 (uk) Композиція рисперидону для ін'єкційної депо-форми
MX2018005340A (es) Proteolisis de direccionamiento a compuestos de quimera y metodos de preparacion y uso de los mismos.
WO2017044894A3 (en) Cartilage-homing peptides
WO2012054500A3 (en) Compositions for drug administration
IN2014MN00333A (es)
PH12015500719A1 (en) Gdf-8-inhibitors
UA111599C2 (uk) Композиція каспофунгіну
MX2012007806A (es) Composiciones farmaceuticas para administracion oral de peptidos de insulina.
MX2011007059A (es) Formulaciones inyectables de toxinas de botulino.
PH12017501294A1 (en) Compounds, compositions and methods useful for cholesterol mobilisation
GB2520897A (en) Compositions and methods for treating cutaneous scarring
EA201370178A1 (ru) Стабильные составы для парентеральной инъекции пептидных лекарственных средств
IN2013DN02524A (es)
MX2011013201A (es) Composiciones para tratar adiccion a drogas y para mejorar comportamiento relacionado a la adiccion.
NZ700296A (en) Compositions and methods for inhibiting cellular adhesion or directing diagnostic or therapeutic agents to rgd binding sites
MX348831B (es) Administración parenteral de tapentadol.
UA109781C2 (uk) Сигма-ліганди для потенціювання аналгетичного ефекту опіоїдів і опіатів при післяопераційному болю і для послаблення залежності від них
MX2016004257A (es) Composiciones oftalmicas basadas en epinefrina para la administracion intraocular y metodos para su frabricacion.
MY168212A (en) A new therapeutical composition containing apomorphine as active ingredient
PH12015501479A1 (en) Diclofenac composition
MD20140123A2 (ro) Agenţi terapeutici optimizaţi pentru administrare subcutanată
TN2012000105A1 (en) Spirolactam derivatives and uses of same
TN2014000060A1 (en) Benzothiazolone compound
MX336278B (es) Composiciones y metodos para la prevencion y el tratamiento de heridas.

Legal Events

Date Code Title Description
FG Grant or registration